Wound care companies are consolidating their position in the market through geographic and portfolio expanding acquisitions.
The global wound care industry is currently valued at $20 billion and is expected to grow at a CAGR of 7% for the next four years to reach approximately $26 billion by 2018.
Median comparable public company multiples are currently tracking at 1.9x latest twelve months revenue while median EBITDA multiples in the same period are 12.4x. There has been a 37% and 55% increase in the sales and EBITDA multiples respectively since 2012.
Median transaction revenue multiples in the last two years are tracking at 4.0x while EBITDA multiples are at 10.9x.
The Wound Care Index has been largely tracking the S&P 500 but has consistently outperformed the S&P 500 since the beginning of 2013.
Recent M&A transactions in the wound care industry show an ongoing trend of companies looking to deepen and strengthen their portfolio through acquisitions.
Most recently in February 2015, Medtronic closed its acquisition of Covidien, the second largest player in the wound care market, for $48 billion. Covidien, based in Ireland, had a 11.4% market share in 2013.
In September 2014 Kinetic Concepts (KCI), LifeCell and Systagenix came together to form Acelity, a global leader in advanced wound care therapeutics and regenerative medicine.